SITC 2019 preview – Nextcure’s time to shine
The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
A ternary outcome for Tocagen
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
Another immuno-oncology mechanism threatens to disappoint
As J&J tears up a licensing deal with Alligator, CD40 agonism might join the likes of Ox40 and IDO as an immuno-oncology approach that has failed to deliver.
Mid-cap investors see Eastern promise in the third quarter
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Mid and small caps provide another rocky ride in the second quarter in 2018
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Mid and small caps provide another rocky ride in the second quarter
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Asco 2018 event analyser – A year of reset expectations
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
Asco 2018 – German Merck’s run at US Merck and other updates
Immuno-oncology is one area where Merck & Co could see a challenge from its historic parent company.
